Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell Lines

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    560 result(s) found for: Cell Lines. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-007139-26 Sponsor Protocol Number: S075LBH501 Start Date*: 2008-04-17
    Sponsor Name:SENDO TECH
    Full Title: A phase II study of the histone deacetylase inhibitor Panobinostat (LBH589) in patients with advanced Small Cell Lung Cancer (SCLC)
    Medical condition: SCLC patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041070 Small cell lung cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000241-49 Sponsor Protocol Number: CNIR178X2201 Start Date*: 2017-12-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma
    Medical condition: Advanced solid tumors and non-Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) CZ (Completed) AT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003657-87 Sponsor Protocol Number: BCNHL Start Date*: 2007-09-14
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Reduced intensity conditioning with high-dose rituximab followed by allogeneic transplantation of hematopoietic cells for the treatment of relapsed/refractory B-cell non Hodgkin’s lymphomas
    Medical condition: B-cell non-Hodgkin lymphomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021613-23 Sponsor Protocol Number: Start Date*: 2010-11-24
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: HYPAZ: An open-label investigation into hypertension induced by pazopanib therapy
    Medical condition: Hypertension induced by pazopanib treatment of various cancer types
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005225-81 Sponsor Protocol Number: VALYM Start Date*: 2021-04-28
    Sponsor Name:LYSARC
    Full Title: A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA
    Medical condition: RELAPSE/REFRACTORY B-CELL LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005265-14 Sponsor Protocol Number: GS-US-548-5918 Start Date*: 2021-12-28
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2 Multi-Arm Study of Magrolimab in Patients with Solid Tumors
    Medical condition: Solid tumours including metastatic non-small cell lung cancer [mNSCLC], metastatic urothelial cancer [mUC], and metastatic small cell lung cancer [mSCLC]
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046725 Urothelial carcinoma ureter metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046730 Urothelial carcinoma urethra metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003657-26 Sponsor Protocol Number: ARD10248 Start Date*: 2012-01-16
    Sponsor Name:sanofi aventis recherche et développement
    Full Title: An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody – maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refrac...
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000639-16 Sponsor Protocol Number: 9090-09 Start Date*: 2012-10-17
    Sponsor Name:Synta Pharmaceuticals Corp
    Full Title: A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non- Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)
    Medical condition: AKL positive advanced non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2015-003362-84 Sponsor Protocol Number: FSJD-DIPG-DC Start Date*: 2016-05-18
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: Phase Ib clinical trial on the safety of immunotherapy with autologous dendritic cells primed with lysate allogeneic tumor lines in patients with diffuse intrinsic pontine glioma ( DIPG )
    Medical condition: Diffuse intrinsic pontine glioma (DIPG)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001207-42 Sponsor Protocol Number: CONFERMER Start Date*: 2014-06-03
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI PARMA
    Full Title: Multicenter randomized trial comparing erlotinib vs mono-chemotherapy in the third-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown
    Medical condition: Third-line treatment in patients with non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000914-12 Sponsor Protocol Number: GASOLINE Start Date*: 2020-06-12
    Sponsor Name:University of Cologne
    Full Title: Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors
    Medical condition: • Melanoma: unresectable stage III with macroscopic lymph node, in transit/satellite metastasis or stage IV after ≥ 2 lines of therapy (incl. checkpoint blockade, BRAF inhibitor) • Prostate carcino...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036921 Prostate carcinoma LLT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10011677 Cutaneous T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020116-11 Sponsor Protocol Number: CAUY922A2206 Start Date*: 2010-11-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in patients with advanced non-small-cell lung cancer who have received at least two lines of prior che...
    Medical condition: patients with advanced non-small-cell lung cancer who have received at least two lines of prior chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002513-36 Sponsor Protocol Number: ASP-1929-301 Start Date*: 2019-08-16
    Sponsor Name:Rakuten Aspyrian, Inc.
    Full Title: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck ...
    Medical condition: Locoregional, recurrent head and neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GR (Completed) BE (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003773-42 Sponsor Protocol Number: PM1183-B-005-14 Start Date*: 2015-03-30
    Sponsor Name:Pharma Mar S.A. Sociedad Unipersonal
    Full Title: A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors.
    Medical condition: Selected Advanced Solid Tumors.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004097-26 Sponsor Protocol Number: PCI-32765FLR2002 Start Date*: 2013-02-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in Subjects with Refractory Follicular Lymphoma
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003716-12 Sponsor Protocol Number: C34004 Start Date*: 2017-07-18
    Sponsor Name:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    Full Title: Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005192-39 Sponsor Protocol Number: 202100663 Start Date*: 2022-04-11
    Sponsor Name:University Medical Center Groningen
    Full Title: Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell lymphoma who are treated with CD19-directed CAR T-cell therapy
    Medical condition: Patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of therapy who fulfill the eligibility criteria for CD19-directed CAR T-cell therapy according the Immune Effe...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003715-38 Sponsor Protocol Number: D4190C00006 Start Date*: 2016-05-12
    Sponsor Name:MedImmune LLC
    Full Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer
    Medical condition: Locally advanced or metastatic squamous or nonsquamous non- small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029520 Non-small cell lung cancer stage IIIA PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005983-28 Sponsor Protocol Number: 1200.23 Start Date*: 2008-05-13
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan ...
    Medical condition: Carcinoma no microcítico de pulmón Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) NL (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004087-31 Sponsor Protocol Number: CLBH589B2203 Start Date*: 2007-02-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy
    Medical condition: Patients with relapsed multiple myeloma who have received at least two prior lines of therapy and whose disease is refractory to the most recent line of therapy. Prior therapy must have included bo...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:20:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA